Clinical application of targeted therapy (BRAF inhibitors with or without MEK inhibitors) and immunotherapy (PD-1 inhibitors and CTLA-4 inhibitors) improve the survival of patients with unresectable melanoma, but the principal therapy for localized melanoma is surgical eradication [3,4]. Here, MAP2K7 is linked to melanoma.